**MINUTES**

**CPIC CONFERENCE CALL**

**ST. JUDE CHILDREN'S RESEARCH HOSPITAL**

**DATE:** March 4th, 2010

**PRESENT:** Mary Relling, Matthew Goetz, Dennis O’Kane, James Hoffman, Teri Klein, Erica Bowton, Uli Broeckel, Kristine Crews, Pat Deverka, Eileen Dolan, Christie Ingram, Jim Kennedy, Joe Ma, Daniel Mueller, Peter O’Donnell, Mike Stein, Todd Skaar, Russell Wilke, Issam Zineh, Whitney Kramer, Leah Sansbury, Sook Wah Yee

| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| --- | --- | --- |
| Discussion of MOUs  Publication of CPIC “guidelines”  Guidelines on guidelines  Update on CYP2D6 guidelines | Teri Klein discussed the draft MOUs that were circulated: one to cover membership in CPIC and another to cover involvement in CPIC publications. It was discussed that the CPIC publications MOU would cover involvement in any publications from CPIC. While most publications would probably cover gene/drug “guidelines” or summaries, it is possible that publications might revolve around other CPIC-related topics (e.g. 3rd party payors and pharmacogenomic testing).  Dr. Klein discussed that she and Dr. Tyndale (PGRN Publications committee) have been successful in garnering interest from a journal (Clinical Pharmacology and Therapeutics) to publish CPIC guidelines.  Drs. Relling and Klein discussed the points raised by Dr. Altman, that the CPIC should carefully consider the use of the term “guidelines,” which often have a formal structure, a method for grading and annotating supportive evidence, and are sometimes adopted or approved by professional organizations. For the last call, Dr. Hoffman pointed out to the group a website devoted to clinical guidelines: <http://www.guidelines.gov/> , illustrating many of these points and the heterogeneity of formats used. It was mentioned that other terms, such as guidances, are less proscriptive, and the term “protocol” connotes research. After some discussion, there was some agreement that the CPIC would favor shooting for the highest standard (i.e. “guideline”), the one most likely to increase the chances for clinical implementation. Although the formats are still unclear, it was also agreed that there should be a common “look and feel” to CPIC guidelines; therefore, the idea that CPIC simultaneously work on at least 2 draft guidelines---one simple (e.g. HLA/abacavir) and one complex (e.g. CYP2D6) in order to try to accommodate a format that will work for multiple types of gene guidelines. It was also agreed that the guidelines must be useful for clinicians.  No progress to report. | MOUs were circulated again to the CPIC membership, with a request for comments and edits due by March 8th. Final MOUs will be circulated, with the goal that all CPIC members will sign and return before next meeting (April 1).  There will likely be further follow-up on the format and titles for the peer-reviewed publications of CPIC work. PharmGKB will continue to be used for additional information, and for updates.  Teri Klein and James Hoffman agreed to work on a draft guideline for HLA/abacavir, accounting for “guidelines” formats.  Todd Sklar will continue to work on the allele variants; Kris Crews will work on drug dosage recommendations (e.g. for codeine). |

Mary V. Relling, PharmD

MVR:vg